Evolus
EOLS· Manufacturing· Fiscal year ends in December
David Moatazedi is the CEO of Evolus and was paid $6.4M in FY2025 (Dec), down 8%.
Executives5
See all- 1David MoatazediPresident and Chief Executive OfficerFY2025
- 2Tatjana MitchellChief Financial OfficerFY2025
- 3Sandra BeaverFormer Chief Financial OfficerFY2025
- 4Rui Avelar, M.D.Chief Medical Officer and Head of Research and DevelopmentFY2025
- 5Tomoko Yamagishi-DresslerFormer Chief Marketing OfficerFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allEvolus paid its 5 named executives $14.6M in total in FY2025 (Dec). CEO David Moatazedi was paid $6.4M of that.
| Name | |||
|---|---|---|---|
| David MoatazediPresident and Chief Executive Officer | |||
| Tatjana MitchellChief Financial Officer | |||
| Sandra BeaverFormer Chief Financial Officer | |||
| Rui Avelar, M.D.Chief Medical Officer and Head of Research and Development | |||
| Tomoko Yamagishi-DresslerFormer Chief Marketing Officer |
of each named executive, from the Summary Compensation Table of each proxy.
Peers18
See allThe FY2025 (Dec) proxy of Evolus names 18 peer companies for pay. Among Evolus and these peers, CEO pay was 7th highest of 8 and total shareholder return was 6th highest of 8.
7th highest of 8in Evolus and its pay peers, FY2025 (Dec) by CEO pay:
6th highest of 8in Evolus and its pay peers, FY2025 (Dec) by total shareholder return:
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Board1
See all- Brady StewartDirector · 3 yr on the boardIndependentAudit, Nominating and Corporate Governance—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Apr 29, 2026 | FY2025 |
| Annual report | 10-K | Mar 3, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 25, 2025 | FY2024 |
| Annual report | 10-K | Mar 4, 2025 | FY2024 |
| Proxy statement | DEF 14A | Apr 26, 2024 | FY2023 |
| Annual report | 10-K | Mar 7, 2024 | FY2023 |